Survey finds transplant patients back treatment despite high costs.
People who underwent a hematopoietic stem cell transplant (HSCT), many of them patients with multiple sclerosis (MS), were supportive of the treatment despite its high costs — and hesitancy and opposition from their neurologists — a survey study showed.
Most surveyed HSCT recipients — about 85% — believed their symptoms were better controlled after the stem cell transplant, and those with MS saw an overall reduction in disability.
However, more than half of the transplant recipients’ neurologists did not support the procedure, and more than 30% did not continue patient care post-treatment, the survey found.
“Our findings indicate that patients are prepared to travel and invest considerable amounts of time and money in HSCT,” the researchers wrote, adding that their study “provides stimulus for large randomized controlled trials” into the use of the experimental treatment.
The study, “A global online study of haematopoietic stem cell transplantation in multiple sclerosis and other neurodegenerative disorders,” was published in Chronic Diseases and Translational Medicine.
Complete story here: https://multiplesclerosisnewstoday.c...ists-hesitant/
People who underwent a hematopoietic stem cell transplant (HSCT), many of them patients with multiple sclerosis (MS), were supportive of the treatment despite its high costs — and hesitancy and opposition from their neurologists — a survey study showed.
Most surveyed HSCT recipients — about 85% — believed their symptoms were better controlled after the stem cell transplant, and those with MS saw an overall reduction in disability.
However, more than half of the transplant recipients’ neurologists did not support the procedure, and more than 30% did not continue patient care post-treatment, the survey found.
“Our findings indicate that patients are prepared to travel and invest considerable amounts of time and money in HSCT,” the researchers wrote, adding that their study “provides stimulus for large randomized controlled trials” into the use of the experimental treatment.
The study, “A global online study of haematopoietic stem cell transplantation in multiple sclerosis and other neurodegenerative disorders,” was published in Chronic Diseases and Translational Medicine.
Complete story here: https://multiplesclerosisnewstoday.c...ists-hesitant/